How the CMO of Sage Therapeutics Positioned a New Indication for FDA Approval

PharmaTalkRadio

English - December 02, 2019 13:00 - 37 minutes - 33.5 MB - ★★★★ - 16 ratings
Science pharmaceutical biotech clinical trials patient engagement immuno-oncology drug delivery r&d Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Addressing the Talent Gap in Biotech - Recruit and Retain

Next Episode: Case Study: Life of a Chief Medical Officer Pre and Post IPO

In this session recorded at the 7th annual Chief Medical Officer Summit, Dr Steve Kanes, Chief Medical Officer, Sage Therapeutics, discusses how a company considered as an "up and comer" in the Cambridge biotech sector navigated the development and approval of the first treatment specifically designed for postpartum depression.

Learn more at theconferenceforum.org